Interpace Financial Statements From 2010 to 2024
| IDXGDelisted Stock | USD 2.20 0.00 0.00% |
Check Interpace Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Interpace Biosciences' main balance sheet or income statement drivers, such as , as well as many indicators such as . Interpace financial statements analysis is a perfect complement when working with Interpace Biosciences Valuation or Volatility modules.
Interpace |
Interpace Biosciences OTC Stock Profit Margin Analysis
Interpace Biosciences' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Interpace Biosciences Profit Margin | (0.59) % |
Most of Interpace Biosciences' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Interpace Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
CompetitionBased on the latest financial disclosure, Interpace Biosciences has a Profit Margin of -0.591%. This is 94.73% lower than that of the Health Care Providers & Services sector and 94.91% lower than that of the Health Care industry. The profit margin for all United States stocks is 53.46% lower than that of the firm.
Interpace Biosciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Interpace Biosciences's current stock value. Our valuation model uses many indicators to compare Interpace Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Interpace Biosciences competition to find correlations between indicators driving Interpace Biosciences's intrinsic value. More Info.Interpace Biosciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Interpace Biosciences' earnings, one of the primary drivers of an investment's value.About Interpace Biosciences Financial Statements
Interpace Biosciences stakeholders use historical fundamental indicators, such as Interpace Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Interpace Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Interpace Biosciences' assets and liabilities are reflected in the revenues and expenses on Interpace Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Interpace Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. Interpace Diag operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 147 people.
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in Interpace OTC Stock
If you are still planning to invest in Interpace Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Interpace Biosciences' history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |